Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From David Wallace
French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.
Canadian firm Genix has acquired 30 ophthalmic generic dossiers from Canagen. Genix expects to begin commercialization from 2022.
Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.
Continuing UK price rises were seen for nefopam in January, according to the latest figures from market researcher WaveData.